About icecure medical ltd - ICCM
IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.
ICCM At a Glance
IceCure Medical Ltd.
7 Ha'Eshel Street
Caesarea, Haifa 3079504
| Phone | 972-4-623-0333 | Revenue | 3.38M | |
| Industry | Medical Specialties | Net Income | -15,057,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 2.674% | |
| Fiscal Year-end | 12 / 2026 | Employees | 69 | |
| View SEC Filings |
ICCM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.48 |
| Price to Book Ratio | 4.929 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.035 |
| Enterprise Value to Sales | 8.911 |
| Total Debt to Enterprise Value | 0.007 |
ICCM Efficiency
| Revenue/Employee | 48,971.014 |
| Income Per Employee | -218,217.391 |
| Receivables Turnover | 10.208 |
| Total Asset Turnover | 0.255 |
ICCM Liquidity
| Current Ratio | 2.613 |
| Quick Ratio | 2.069 |
| Cash Ratio | 1.844 |
ICCM Profitability
| Gross Margin | 32.82 |
| Operating Margin | -446.70 |
| Pretax Margin | -445.605 |
| Net Margin | -445.605 |
| Return on Assets | -113.792 |
| Return on Equity | -188.779 |
| Return on Total Capital | -162.462 |
| Return on Invested Capital | -186.742 |
ICCM Capital Structure
| Total Debt to Total Equity | 2.398 |
| Total Debt to Total Capital | 2.341 |
| Total Debt to Total Assets | 1.563 |
| Long-Term Debt to Equity | 0.144 |
| Long-Term Debt to Total Capital | 0.14 |